Lanvin Group Holdings Limited (LANV)

$2.16 -0.02 (-0.80%)
Market Cap 330.65M
Revenue (ttm) 461.25M
Net Income (ttm) -139.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -30.34%
Debt to Equity Ratio 1.36
Volume 28,618
Avg Vol 52,532
Day's Range N/A - N/A
Shares Out 145.02M
Stochastic %K 42%
Beta -0.34
Analysts Strong Buy
Price Target $1.90

Latest News on LANV

Lanvin Group to Report 2024 Full-Year Audited Results on April 30, 2025

Apr 18, 2025, 6:00 AM EDT - 10 days ago

Lanvin Group to Report 2024 Full-Year Audited Results on April 30, 2025

PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage

Mar 4, 2025, 11:00 AM EST - 7 weeks ago

PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage

Lanvin Group Holdings Limited (LANV) 2024 Sales/Trading Statement Call Transcript

Feb 28, 2025, 10:12 AM EST - 2 months ago

Lanvin Group Holdings Limited (LANV) 2024 Sales/Trading Statement Call Transcript

Lanvin Group Prioritizes Creative Renewal and Operational Agility Amid Evolving Luxury Landscape

Feb 28, 2025, 7:30 AM EST - 2 months ago

Lanvin Group Prioritizes Creative Renewal and Operational Agility Amid Evolving Luxury Landscape

Lanvin Group to Report 2024 Full-Year Preliminary Revenues on February 28, 2025

Feb 17, 2025, 5:00 AM EST - 2 months ago

Lanvin Group to Report 2024 Full-Year Preliminary Revenues on February 28, 2025

Lanvin Group Announces Leadership and Board Changes to Accelerate Growth and Strategic Initiatives

Jan 16, 2025, 8:00 AM EST - 3 months ago

Lanvin Group Announces Leadership and Board Changes to Accelerate Growth and Strategic Initiatives

PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia

Jan 6, 2025, 10:00 AM EST - 4 months ago

PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia

Lanvin Group Holdings Limited to Hold Annual General Meeting on December 11, 2024

Nov 19, 2024, 5:00 AM EST - 5 months ago

Lanvin Group Holdings Limited to Hold Annual General Meeting on December 11, 2024

PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada

Sep 4, 2024, 9:00 AM EDT - 8 months ago

PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada

Lanvin Group Holdings Limited (LANV) Q2 2024 Earnings Call Transcript

Aug 26, 2024, 10:22 AM EDT - 8 months ago

Lanvin Group Holdings Limited (LANV) Q2 2024 Earnings Call Transcript

Lanvin Group Posts Revenue of €171 million in H1 2024

Aug 26, 2024, 6:00 AM EDT - 8 months ago

Lanvin Group Posts Revenue of €171 million in H1 2024

SERGIO ROSSI APPOINTS PAUL ANDREW CREATIVE DIRECTOR

Jul 24, 2024, 9:13 AM EDT - 9 months ago

SERGIO ROSSI APPOINTS PAUL ANDREW CREATIVE DIRECTOR

LANVIN APPOINTS PETER COPPING ARTISTIC DIRECTOR

Jun 27, 2024, 9:30 AM EDT - 10 months ago

LANVIN APPOINTS PETER COPPING ARTISTIC DIRECTOR

Regis Rimbert Named CEO of Wolford AG

Jun 13, 2024, 9:45 AM EDT - 11 months ago

Regis Rimbert Named CEO of Wolford AG

ees Europe: Battery Storage – Powerbanks for the Energy Transition

Jun 4, 2024, 8:49 AM EDT - 11 months ago

ees Europe: Battery Storage – Powerbanks for the Energy Transition

BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO

May 29, 2024, 2:30 PM EDT - 11 months ago

BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO

Lanvin Group Holdings Limited (LANV) Q4 2023 Earnings Call Transcript

Apr 30, 2024, 11:56 AM EDT - 1 year ago

Lanvin Group Holdings Limited (LANV) Q4 2023 Earnings Call Transcript

Lanvin Group Shows Resiliency in Sales and On-Track Margin Improvement in 2023

Apr 30, 2024, 6:00 AM EDT - 1 year ago

Lanvin Group Shows Resiliency in Sales and On-Track Margin Improvement in 2023

Lanvin Group to Report 2023 Full-Year Audited Results on April 30, 2024

Apr 22, 2024, 6:00 AM EDT - 1 year ago

Lanvin Group to Report 2023 Full-Year Audited Results on April 30, 2024

Analyses Find Patients With Polycythemia Vera (PV) Treated With BESREMi® (ropeginterferon alfa-2b) Had Increased Probability of Achieving Complete Hematologic Response

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Analyses Find Patients With Polycythemia Vera (PV) Treated With BESREMi® (ropeginterferon alfa-2b) Had Increased Probability of Achieving Complete Hematologic Response

Lanvin Group Holdings Limited (LANV) 2023 Sales/ Trading Statement Call Transcript

Feb 21, 2024, 10:23 AM EST - 1 year ago

Lanvin Group Holdings Limited (LANV) 2023 Sales/ Trading Statement Call Transcript

Lanvin Group Resiliency was Key in 2023, Preliminary Revenues Up 1% Year-on-Year

Feb 21, 2024, 5:00 AM EST - 1 year ago

Lanvin Group Resiliency was Key in 2023, Preliminary Revenues Up 1% Year-on-Year

Lanvin Group to Report 2023 Full-Year Preliminary Revenues on February 21, 2024

Feb 6, 2024, 5:00 AM EST - 1 year ago

Lanvin Group to Report 2023 Full-Year Preliminary Revenues on February 21, 2024

Lanvin Group Holdings Limited to Hold Annual General Meeting on December 21, 2023

Dec 8, 2023, 6:43 AM EST - 1 year ago

Lanvin Group Holdings Limited to Hold Annual General Meeting on December 21, 2023

Lanvin Group Announces New CEO

Dec 8, 2023, 5:00 AM EST - 1 year ago

Lanvin Group Announces New CEO

Lanvin Group Posts 6.4% Y-o-Y Revenue Growth In H1 2023

Aug 30, 2023, 5:33 AM EDT - 1 year ago

Lanvin Group Posts 6.4% Y-o-Y Revenue Growth In H1 2023

Lanvin Group to Report 2023 First-Half Results on August 30, 2023

Aug 16, 2023, 5:00 AM EDT - 1 year ago

Lanvin Group to Report 2023 First-Half Results on August 30, 2023

Lanvin Group Posts Record Sales and Continued Margin Improvement in 2022. Revenues Up 37% Year-over-Year.

Apr 20, 2023, 6:46 AM EDT - 2 years ago

Lanvin Group Posts Record Sales and Continued Margin Improvement in 2022. Revenues Up 37% Year-over-Year.

Lanvin Group to Report 2022 Full-Year Audited Results on April 20, 2023

Apr 10, 2023, 6:00 AM EDT - 2 years ago

Lanvin Group to Report 2022 Full-Year Audited Results on April 20, 2023

Lanvin's IPO Strengthens The Fall Winter 2023 Collection

Mar 6, 2023, 1:26 PM EST - 2 years ago

Lanvin's IPO Strengthens The Fall Winter 2023 Collection

Lanvin Group Achieves Record Sales in 2022

Feb 17, 2023, 6:00 AM EST - 2 years ago

Lanvin Group Achieves Record Sales in 2022

Lanvin Group to Report 2022 Full-Year Preliminary Revenues on February 17, 2023

Feb 10, 2023, 8:00 AM EST - 2 years ago

Lanvin Group to Report 2022 Full-Year Preliminary Revenues on February 17, 2023

Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera

Feb 2, 2023, 8:00 AM EST - 2 years ago

Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera

Lanvin Group Plans to Announce 2022 Full-Year Preliminary Revenue Results on February 17, 2023; Announces Management Change

Jan 31, 2023, 8:00 AM EST - 2 years ago

Lanvin Group Plans to Announce 2022 Full-Year Preliminary Revenue Results on February 17, 2023; Announces Management Change

Newly Listed Lanvin Leaves Investors Blowing Hot And Cold

Jan 9, 2023, 2:30 AM EST - 2 years ago

Newly Listed Lanvin Leaves Investors Blowing Hot And Cold

Lanvin Group Appoints Veteran Entertainment Executive, Ceci Kurzman as a New Independent Director; and Announces Changes in Composition of Board Committees

Jan 6, 2023, 4:30 PM EST - 2 years ago

Lanvin Group Appoints Veteran Entertainment Executive, Ceci Kurzman as a New Independent Director; and Announces Changes in Composition of Board Committees

Lanvin Group Debuts on NYSE under Ticker "LANV"

Dec 15, 2022, 4:30 PM EST - 2 years ago

Lanvin Group Debuts on NYSE under Ticker "LANV"

New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey

Dec 12, 2022, 10:00 AM EST - 2 years ago

New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey

Lanvin Group and Primavera Capital Acquisition Corporation Announce Updates in Relation to Business Combination

Dec 5, 2022, 8:30 AM EST - 2 years ago

Lanvin Group and Primavera Capital Acquisition Corporation Announce Updates in Relation to Business Combination

Lanvin Group and Primavera Capital Acquisition Corp. Announces Effectiveness of Registration Statement and Extraordinary General Meeting Date for Proposed Business Combination

Nov 4, 2022, 8:45 AM EDT - 2 years ago

Lanvin Group and Primavera Capital Acquisition Corp. Announces Effectiveness of Registration Statement and Extraordinary General Meeting Date for Proposed Business Combination